Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C

Open source

DOI: 10.1038/s41591-025-04106-7
Published: 2026 Jan
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-04106-7,
  title = {Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.},
  author = {Edison P and Femminella GD and Ritchie C and Nowell J and Holmes C and Walker Z and Ridha B and Raza S and Livingston NR and Frangou E and Love S and Williams G and Lawrence R and Mcfarlane B and Archer H and Coulthard E and Underwood BR and Koranteng P and Karim S and Bannister C and Perneczky R and Prasanna A and Junaid K and McGuinness B and Nilforooshan R and Macharouthu A and Donaldson A and Thacker S and Russell G and Malik N and Mate V and Knight L and Kshemendran S and Holscher C and Mansouri A and Chester-Jones M and Holmes J and Tan T and Williams S and Ashraf A and Brooks DJ and Harrison J and Hinz R and Tadros G and Passmore AP and Ballard C},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-025-04106-7},
  url = {https://doi.org/10.1038/s41591-025-04106-7}
}

RIS

TY  - JOUR
TI  - Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
AU  - Edison P
AU  - Femminella GD
AU  - Ritchie C
AU  - Nowell J
AU  - Holmes C
AU  - Walker Z
AU  - Ridha B
AU  - Raza S
AU  - Livingston NR
AU  - Frangou E
AU  - Love S
AU  - Williams G
AU  - Lawrence R
AU  - Mcfarlane B
AU  - Archer H
AU  - Coulthard E
AU  - Underwood BR
AU  - Koranteng P
AU  - Karim S
AU  - Bannister C
AU  - Perneczky R
AU  - Prasanna A
AU  - Junaid K
AU  - McGuinness B
AU  - Nilforooshan R
AU  - Macharouthu A
AU  - Donaldson A
AU  - Thacker S
AU  - Russell G
AU  - Malik N
AU  - Mate V
AU  - Knight L
AU  - Kshemendran S
AU  - Holscher C
AU  - Mansouri A
AU  - Chester-Jones M
AU  - Holmes J
AU  - Tan T
AU  - Williams S
AU  - Ashraf A
AU  - Brooks DJ
AU  - Harrison J
AU  - Hinz R
AU  - Tadros G
AU  - Passmore AP
AU  - Ballard C
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-025-04106-7
UR  - https://doi.org/10.1038/s41591-025-04106-7
ER  -

APA

P, E., GD, F., C, R., J, N., C, H., Z, W., B, R., S, R., NR, L., E, F., S, L., G, W., R, L., B, M., H, A., E, C., BR, U., P, K., S, K., C, B., R, P., A, P., K, J., B, M., R, N., A, M., A, D., S, T., G, R., N, M., V, M., L, K., S, K., C, H., A, M., M, C., J, H., T, T., S, W., A, A., DJ, B., J, H., R, H., G, T., AP, P., & C, B. (2026). Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.. Nature medicine. https://doi.org/10.1038/s41591-025-04106-7

Source records

pubmed · retrieved 2026-09-26T07:10:49.886Z